Key Takeaways
- ClarityDX Prostate, a blood-based diagnostic tool powered by AI, helps healthcare providers in the Middle East identify men at risk of aggressive prostate cancer, improving early detection and treatment outcomes.
- Nanostics and OncoHelix have partnered to offer the ClarityDX Prostate test through the OncoHelix-coLAB facility in Abu Dhabi, expanding access to advanced prostate cancer diagnostics in the Middle East.
- The ClarityDX Prostate test provides a non-invasive, data-driven alternative to invasive procedures like biopsies, offering men and healthcare providers more informed decisions on managing prostate cancer risk.
Nanostics Inc., a precision health company focused on developing advanced diagnostic tests, has formed a strategic partnership with OncoHelix to bring the ClarityDX Prostate® diagnostic tool to healthcare providers and men across the Middle East. This collaboration introduces a powerful AI-driven diagnostic tool aimed at improving the early detection of aggressive prostate cancer, empowering healthcare providers with data-driven insights for better patient outcomes.
ClarityDX Prostate is a non-invasive, blood-based diagnostic tool that uses a combination of biological data, clinical information, and artificial intelligence (AI) models to assess the risk of aggressive prostate cancer. The test provides critical support to men and their healthcare teams by determining whether further diagnostic procedures, such as a biopsy, are needed after high prostate-specific antigen (PSA) levels or abnormal digital rectal examination (DRE) results. This innovative tool marks a significant advancement in prostate cancer screening, particularly for men at risk of aggressive forms of the disease.
OncoHelix, a leader in precision diagnostics in the Middle East and North Africa (MENA) region, will deliver the ClarityDX Prostate test through its state-of-the-art OncoHelix-coLAB laboratory, located within Burjeel Medical City in Abu Dhabi. The facility, a joint venture between OncoHelix and Burjeel Holdings, is known for providing cutting-edge molecular diagnostics and immune profile testing. By incorporating ClarityDX Prostate into its offerings, OncoHelix aims to enhance the diagnostic landscape for prostate cancer in the region, enabling earlier detection and improved treatment outcomes for men at risk of aggressive prostate cancer.
Nanostics and OncoHelix Bring Diagnostic Tool ClarityDX Prostate to the Middle East, Advancing Early Detection of Aggressive Prostate Cancer
Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta, emphasized the global significance of this Alberta-developed technology, stating, “Partnering with OncoHelix, another Alberta-based company, to bring ClarityDX Prostate to men in the Middle East shows how relevant Alberta-developed technology has become on the global stage. ClarityDX Prostate is a powerful diagnostic tool that can help identify men with aggressive prostate cancer early, leading to better treatment outcomes.”
Faisal Khan, CEO of OncoHelix, echoed these sentiments, expressing enthusiasm for the partnership. “We are thrilled to partner with Nanostics to bring the ClarityDX Prostate test to the Middle East. This advanced diagnostic tool will empower healthcare providers with better, data-driven insights, enabling earlier detection and more targeted treatment for men at risk of aggressive prostate cancer in the region,” he said.
Prostate cancer is one of the most common cancers affecting men worldwide, and aggressive forms of the disease can be particularly challenging to diagnose and treat. The ClarityDX Prostate test provides an essential solution to this challenge by offering a non-invasive, accurate method for assessing prostate cancer risk, thus reducing the need for unnecessary biopsies and improving patient care.
Nanostics and OncoHelix Partner to Enhance Prostate Cancer Diagnostics in the Middle East with ClarityDX Prostate
Nanostics and OncoHelix aim to address the growing demand for advanced diagnostic tools that can guide clinical decision-making and improve patient outcomes. The partnership will provide healthcare providers in the Middle East with access to one of the most advanced diagnostic technologies available, significantly enhancing the region’s capacity to manage prostate cancer.
In addition to its availability in the Middle East, ClarityDX Prostate is also offered in the USA as CDX Prostate through Protean BioDiagnostics and in most Canadian provinces through Nanostics’ CPSA-accredited lab in Alberta. This partnership signifies a critical step in expanding the global reach of ClarityDX Prostate, making it available to more men worldwide who could benefit from early and accurate diagnosis of aggressive prostate cancer.
As Nanostics and OncoHelix continue to collaborate, the introduction of ClarityDX Prostate into the Middle Eastern market is poised to play a pivotal role in improving prostate cancer diagnostics and treatment across the region. With this partnership, both companies are committed to providing healthcare providers with the tools they need to offer men better, more personalized cancer care.
Resource: Nanostics, September 26, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
